参一胶囊在NSCLC患者维持治疗中的疗效分析
|
摘要
目的探讨参一胶囊在非小细胞肺癌(NSCLC)患者维持治疗中的临床疗效。方法在该医院2017年9月—2018年9月期间诊治的NSCLC患者中方便选取40例作研究对象,均在放化疗后进行维持治疗;将放化疗后仅定期随访观察者设为对照组(n=20),将在放化疗后应用参一胶囊进行维持治疗者设为研究组(n=20),就2组患者维持治疗效果、炎症因子以及免疫功能变化进行统计学分析。结果①研究组患者肿瘤控制率是55.0%,高于对照组的20.0%(χ2=5.227,P=0.22);②研究组患者治疗后的CD4+/CD8+水平高于对照组,而该组TNF-α水平均低于对照组(t=9.847、2.819,P=0.000、0.004)。结论参一胶囊在NSCLC患者维持治疗中的疗效显著,可改善肿瘤控制效果,促使TNF-α呈现低表达状态,并提高患者放化疗后免疫功能,值得借鉴。
Objective To investigate the clinical efficacy of Shenyi Capsule in the maintenance of non-small cell lung cancer(NSCLC) patients. Methods 40 patients with NSCLC who were treated in the hospital from September 2017 to September 2018 were convenient selected and enrolled in the study. All patients were treated with chemoradiotherapy. After radiotherapy and chemotherapy, only regular follow-up observations were used in the control group(n = 20), after the use of chemoradiotherapy, the application of Shenyi capsule for maintenance treatment was set as the study group(n=20), and the maintenance effect, inflammatory factors and immune function changes were statistically analyzed in the two groups. Results1.The tumor control rate of the study group was 55.0%, which was higher than 20.0% of the control group(χ2=5.227, P=0.22). 2.The CD4+/CD8+level of the study group was higher than that of the control group, and the TNF-α level of this group was lower than that of the control group(t=9.847, 2.819 P=0.000, 0.004). Conclusion Shenyi Capsule has a significant effect in the maintenance of NSCLC patients, which can improve the tumor control effect, promote the low expression status of TNF-α, and improve the immune function of patients after radiotherapy and chemotherapy. It is worth learning.
Objective To investigate the clinical efficacy of Shenyi Capsule in the maintenance of non-small cell lung cancer(NSCLC) patients. Methods 40 patients with NSCLC who were treated in the hospital from September 2017 to September 2018 were convenient selected and enrolled in the study. All patients were treated with chemoradiotherapy. After radiotherapy and chemotherapy, only regular follow-up observations were used in the control group(n = 20), after the use of chemoradiotherapy, the application of Shenyi capsule for maintenance treatment was set as the study group(n=20), and the maintenance effect, inflammatory factors and immune function changes were statistically analyzed in the two groups. Results1.The tumor control rate of the study group was 55.0%, which was higher than 20.0% of the control group(χ2=5.227, P=0.22). 2.The CD4+/CD8+level of the study group was higher than that of the control group, and the TNF-α level of this group was lower than that of the control group(t=9.847, 2.819 P=0.000, 0.004). Conclusion Shenyi Capsule has a significant effect in the maintenance of NSCLC patients, which can improve the tumor control effect, promote the low expression status of TNF-α, and improve the immune function of patients after radiotherapy and chemotherapy. It is worth learning.
引文
[1]牛朝霞,李宁宁,梁芳.紫杉醇化疗联合参一胶囊对晚期非小细胞肺癌患者的疗效及安全性[J].世界中医药,2016,11(7):1265-1267.
[2]白钰,吕德胜,李默,等.单孔与单操作孔胸腔镜在NSCLC手术治疗中的价值对比分析[J].医学与哲学,2016,37(10):31-33.
[3]郑心婷,林丽珠.应用CT灌注成像观察益气除痰方加减治疗中晚期非小细胞肺癌的疗效[J].中国中西医结合杂志,2016,36(2):155-159.
[4]谭栋,何盟国,沈乃营,等.参一胶囊联合腹腔镜解剖性肝段切除术治疗老年原发性肝癌的临床研究[J].中国中西医结合外科杂志,2018,24(1):21-26.
[5]阎吕军,黄少江.乌苯美司胶囊联合参一胶囊治疗晚期非小细胞肺癌安全性及疗效观察[J].现代中西医结合杂志,2017,26(6):624-626.
[6]梁俊燕,韩秀文.人参皂苷Rg3配合化疗对中晚期非小细胞肺癌患者血清中TGF-α、TGF-β1和VEGF的影响[J].临床肺科杂志,2016,21(9):1675-1678.
[7]Yang J,Ramalingam SS,Jnne PA,et al.LBA2_PR:Osimertinib(AZD9291)in pre-treated pts with T790M-positive advanced NSCLC:updated Phase 1(P1)and pooled Phase 2(P2)results[J].Journal of Thoracic Oncology,2016,11(4):S152-S153.
[8]Gainor JF,Tan DS,De PT,et al.Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib[J].Clinical Cancer Research,2016,21(12):2745-2752.
[9]虞倩,郭玮.数字PCR技术在NSCLC患者EGFR-TKI靶向治疗检测中的应用[J].中华检验医学杂志,2016,39(3):161-164.
[10]王国华,刘凤玲,张振山,等.参一胶囊联合化疗治疗晚期非小细胞肺癌疗效观察与血清MMP-9及TIMP-1变化[J].现代肿瘤医学,2017,25(6):896-901.
[2]白钰,吕德胜,李默,等.单孔与单操作孔胸腔镜在NSCLC手术治疗中的价值对比分析[J].医学与哲学,2016,37(10):31-33.
[3]郑心婷,林丽珠.应用CT灌注成像观察益气除痰方加减治疗中晚期非小细胞肺癌的疗效[J].中国中西医结合杂志,2016,36(2):155-159.
[4]谭栋,何盟国,沈乃营,等.参一胶囊联合腹腔镜解剖性肝段切除术治疗老年原发性肝癌的临床研究[J].中国中西医结合外科杂志,2018,24(1):21-26.
[5]阎吕军,黄少江.乌苯美司胶囊联合参一胶囊治疗晚期非小细胞肺癌安全性及疗效观察[J].现代中西医结合杂志,2017,26(6):624-626.
[6]梁俊燕,韩秀文.人参皂苷Rg3配合化疗对中晚期非小细胞肺癌患者血清中TGF-α、TGF-β1和VEGF的影响[J].临床肺科杂志,2016,21(9):1675-1678.
[7]Yang J,Ramalingam SS,Jnne PA,et al.LBA2_PR:Osimertinib(AZD9291)in pre-treated pts with T790M-positive advanced NSCLC:updated Phase 1(P1)and pooled Phase 2(P2)results[J].Journal of Thoracic Oncology,2016,11(4):S152-S153.
[8]Gainor JF,Tan DS,De PT,et al.Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib[J].Clinical Cancer Research,2016,21(12):2745-2752.
[9]虞倩,郭玮.数字PCR技术在NSCLC患者EGFR-TKI靶向治疗检测中的应用[J].中华检验医学杂志,2016,39(3):161-164.
[10]王国华,刘凤玲,张振山,等.参一胶囊联合化疗治疗晚期非小细胞肺癌疗效观察与血清MMP-9及TIMP-1变化[J].现代肿瘤医学,2017,25(6):896-901.